Family History
448 articles
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Meet the Researcher: Nicolette Juliana Rodriguez, M.D., M.P.H.
Learn more about the research interests of Nicolette Rodriguez, M.D., M.P.H., one of the young investigators Let’s Win sponsored at AACR.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
A Long Journey That Began With Pancreatitis
Paul Suntup’s diagnosis of acinar cell pancreatic cancer was just the start of a long treatment journey, but he’s still here.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
I Wanted Immunotherapy!
When Daniel Miller was diagnosed with pancreatic cancer he knew he didn’t want chemotherapy—he wanted immunotherapy!